Hamid Danesh, MD
Internal Medicine · Lowell, MANPI 1811961196
Payments from drug & device makers
Across 72 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$303
- Lilly USA, LLC$123
- Indivior Inc.$117
- GSK$115
- Pfizer$107
- Inspire Medical Systems, Inc.$69
- plus $609 from 17 others
What the payments were for
- Food & beverage$1,40798%
- Education$352%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $303 |
| Lilly USA, LLC | 7 | $123 |
| Indivior Inc. | 6 | $117 |
| GSK | 6 | $115 |
| Pfizer | 4 | $107 |
| Inspire Medical Systems, Inc. | 3 | $69 |
| Boehringer Ingelheim | 3 | $55 |
| AstraZeneca | 3 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Alkermes, Inc. | 3 | $44 |
| Bayer | 2 | $44 |
| Braeburn Inc. | 2 | $41 |
| Novo Nordisk | 2 | $39 |
| Exact Sciences | 2 | $39 |
| AbbVie | 2 | $37 |
| Alnylam Pharmaceuticals Inc. | 1 | $34 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $32 |
| Phathom Pharmaceuticals, Inc. | 2 | $30 |
| Pear Therapeutics (US), Inc. | 1 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| CSL Behring | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
How this compares
$1,442 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 85 | $106,710 |
| OzempicSemaglutide | 87 | $82,788 |
| EliquisApixaban | 84 | $79,537 |
| JanuviaSitagliptin Phosphate | 59 | $64,165 |
| JardianceEmpagliflozin | 62 | $49,930 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $49,929 |
| SublocadeBuprenorphine | 13 | $26,013 |
| XareltoRivaroxaban | 20 | $24,271 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 43 | $20,740 |
| OxycontinOxycodone Hcl | 26 | $19,234 |
| LinzessLinaclotide | 27 | $15,771 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 96 | $13,198 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,327 |
| TradjentaLinagliptin | 14 | $8,321 |
| Varenicline Tartrate | 25 | $8,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $123 | $106,71085 claims |
| Novo NordiskOzempic | $39 | $82,78887 claims |
| PfizerEliquis | $107 | $79,53784 claims |
| Boehringer IngelheimJardiance, Tradjenta | $55 | $58,25276 claims |
| GileadBiktarvy | $303 | $49,92911 claims |
| Indivior Inc.Sublocade, Suboxone | $117 | $46,75256 claims |
| AbbVieLinzess | $37 | $15,77127 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $115 | $11,62225 claims |
| AstraZenecaSymbicort | $53 | $5,35224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.
Other internal medicine in Lowell
- Noopur RajeBoston$19.9M
- Michael McCartneyNewburyport$17.6M
- Rebecca HeistBoston$17.4M
- Richard PlattBoston$13.5M
- Ryan CorcoranBoston$11.4M
- Joyce LiuCharlestown$10.3M
- Elizabeth LeeBoston$9.8M
- Adnan DahdulSpringfield$8.8M
- Ryan SullivanCambridge$8.5M
- Xiuning leBoston$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.